Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment. Issue 3 (March 2023)

• Record Type: Journal Article
• Authors: Kaiki, Yuki; Ohge, Hiroki; Ikawa, Kazuro; Uegami, Shinnosuke; Watadani, Yusuke; Shigemoto, Norifumi; Hirano, Toshinori; Yoshimura, Kosuke; Kitagawa, Hiroki; Morikawa, Norifumi; Takahashi, Shinya
• Is Part Of: Journal of infection and chemotherapy. Volume 29:Issue 3(2023)
• Page Start: 309
• Page End: 315
• Publication Date: 2023-03
• Subjects: Cefmetazole -- Pharmacokinetics -- Pharmacodynamics -- ESBL -- Carbapenem-sparing -- Lower gastrointestinal surgery; AUC Area under curve -- Cmax Maximum concentration -- CMZ Cefmetazole -- ESBL extended-spectrum β-lactamase -- MIC Minimum inhibitory concentration -- PK Pharmacokinetic -- PD pharmacodynamic -- SSI Surgical site infection; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2022.12.005
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: Introduction: Cefmetazole (CMZ) has gained interest as a carbapenem-sparing alternative to the epidemic of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E). In this study, we investigated the pharmacokinetics (PK) of CMZ in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue to assess the dosing regimen needed to achieve pharmacodynamic (PD) goals at the target site. Methods: Patients scheduled for elective lower gastrointestinal surgery were intravenously administered CMZ. Plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue samples were collected after CMZ infusion and during the surgery, and CMZ concentrations were measured. The non-compartmental and compartmental PK parameters were estimated and used to evaluate site-specific PD target attainment. Results: A total of 38 plasma, 27 peritoneal fluid, 36 peritoneum, and 38 subcutaneous adipose tissue samples were collected from 10 patients. The non-compartmental PK analysis revealed the ratios of the mean area under the drug concentration-time curve (AUC0–3.5 h ) of peritoneal fluid-to-plasma, peritoneum-to-plasma, and subcutaneous adipose tissue-to-plasma were 0.60, 0.36, and 0.11, respectively. The site-specific PD target attainment analyses based on the breakpoints for ESBL-E per the Japanese surgical site infection (SSI) surveillance (MIC90 = 8 mg/L) revealed that 2 g CMZ every 3.5 h achieved desired bactericidal effect at all sites and 2 g CMZ every 6 h achieved PD goals at peritoneum and peritoneal fluid. Conclusion: These findings clarify the PK of CMZ in abdominal tissues and could help decide optimal dosing regimens to treat intra-abdominal infection and prophylaxis of SSI.